Table 1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in &lt;i&gt;SETD2&lt;/i&gt;&lt;i&gt;-&lt;/i&gt;Altered Advanced Solid Tumor Malignancies (NCI 10170)

Table 1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)

Edward Maldonado(University of California, San Francisco), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), Arash Rezazadeh Kalebasty(University of California, Irvine), Nikolaos A. Trikalinos(University of California, San Francisco), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Emily K. Bergsland(University of California, San Francisco), Timothy F. Burns(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Geoffrey I. Shapiro(Brigham and Women's Hospital), Alan Ashworth(University of California, San Francisco), Patricia LoRusso(Yale Cancer Center), W. Kimryn Rathmell(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Naoko Takebe(National Cancer Institute), Pamela N. Münster(University of California, San Francisco), Scott A. Boerner, Celene Balido(University of California, San Francisco), Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Gregor Krings(Cleveland Clinic), Mamta Parikh(UC Davis Comprehensive Cancer Center)

Unknown

July 23, 2024

Cited by 0